IMCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immunocore Holdings PLC (IMCR) is not a strong buy at this time for a beginner investor with a long-term strategy. The technical indicators are neutral to bearish, options data suggests bearish sentiment, and there are no significant positive catalysts or recent news to drive immediate growth. While the company's financials show YoY improvement, the lack of strong analyst confidence and the downgrade by Jefferies further weigh against a buy recommendation.
The technical indicators for IMCR are neutral to bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 46.581, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point of 30.383, with resistance at 31.328 and support at 29.437.
The company reported YoY revenue growth of 24.30% in Q4 2025, and net income improved by 26.46% YoY, indicating some operational progress.
Jefferies downgraded the stock to Hold from Buy, citing limited upside without pipeline success and a moderate total addressable market. The bearish options sentiment (high put-call ratios) and lack of recent news or significant trading trends further weigh against the stock.
In Q4 2025, revenue increased by 24.30% YoY to $104.48M, net income improved by 26.46% YoY to -$30.06M, and EPS rose by 25.53% YoY to -0.59. However, gross margin dropped slightly by -2.21% YoY to 97.41%.
Analyst sentiment is mixed to negative. Jefferies downgraded the stock to Hold with a price target of $33, citing limited growth potential. Mizuho raised the price target to $38 but maintained a Neutral rating. Morgan Stanley raised the price target to $40 with an Equal Weight rating. UBS upgraded the stock to Buy with a price target of $55, but this is an outlier among recent ratings.
